Thiazolidinone congeners as central nervous system active agents.
3-(Benzylidene amino)-2-imino-4-thiazolidinones (IIa-c) synthesized by cyclization of substituted thiosemicarbazones (Ia-c) were converted into 2-amino-3-(substituted benzylamino)-4-thiazolidinones (IIIa-c), 2-imino-3-(alpha-aryl azo benzylidene) amino-4-thiazolidinones (IVa-f) and 2-(2-amino-4-oxo-3-thiazolidinyl)-3-aryl-4-isothiazolidinones (VIa-c), IVa-f were finally converted into 5-(arylamino methyl)-2-imino-3-(alpha-aryl azobenzylidene)-amino-4-thiazolidinones (Va-l). These compounds III, V and VI were evaluated for their monoamine oxidase (MAO) inhibitory activity in vitro and various CNS activities in vivo. Some of the compounds exhibited promising CNS activity.
Tripathi
M
M
Department of Pharmacology and Therapeutics, King George's Medical College, Lucknow, India.
Verma
M
M
Gujrati
V R
VR
Palit
G
G
Shanker
K
K
D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000201:enzymology; D002491:Central Nervous System Agents / Q000138:chemical synthesis* / Q000494:pharmacology / Q000633:toxicity; D004357:Drug Synergism; D005260:Female; D006380:Helplessness, Learned; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D008996:Monoamine Oxidase Inhibitors / Q000138:chemical synthesis / Q000494:pharmacology; D010862:Pilocarpine / Q000494:pharmacology; D051381:Rats; D012110:Reserpine / Q000037:antagonists & inhibitors; D012472:Salivation / Q000187:drug effects; D013844:Thiazoles / Q000138:chemical synthesis* / Q000494:pharmacology / Q000633:toxicity
D002491:Central Nervous System Agents; D008996:Monoamine Oxidase Inhibitors; D013844:Thiazoles; D010862:Pilocarpine; D012110:Reserpine; D000661:Amphetamine